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Background: The conditionally essential nutrient, L-carnitine, plays a critical role in a number of physiological
processes vital to normal neonatal growth and development. We conducted a systematic evaluation of the
developmental changes in key L-carnitine homeostasis mechanisms in the postnatal rat to better understand the
interrelationship between these pathways and their correlation to ontogenic changes in L-carnitine levels during
postnatal development.
Methods: mRNA expression of heart, kidney and intestinal L-carnitine transporters, liver γ-butyrobetaine
hydroxylase (Bbh) and trimethyllysine hydroxylase (Tmlh), and heart carnitine palmitoyltransferase (Cpt) were
measured using quantitative RT-PCR. L-Carnitine levels were determined by HPLC-UV. Cpt and Bbh activity were
measured by a spectrophotometric method and HPLC, respectively.
Results: Serum and heart L-carnitine levels increased with postnatal development. Increases in serum L-carnitine
correlated significantly with postnatal increases in renal organic cation/carnitine transporter 2 (Octn2) expression,
and was further matched by postnatal increases in intestinal Octn1 expression and hepatic γ-Bbh activity. Postnatal
increases in heart L-carnitine levels were significantly correlated to postnatal increases in heart Octn2 expression.
Although cardiac high energy phosphate substrate levels remained constant through postnatal development,
creatine showed developmental increases with advancing neonatal age. mRNA levels of Cpt1b and Cpt2
significantly increased at postnatal day 20, which was not accompanied by a similar increase in activity.
Conclusions: Several L-carnitine homeostasis pathways underwent significant ontogenesis during postnatal
development in the rat. This information will facilitate future studies on factors affecting the developmental
maturation of L-carnitine homeostasis mechanisms and how such factors might affect growth and development.
Keywords: L-Carnitine, Homeostasis, Postnatal development, RatIntroduction
L-Carnitine is a conditionally essential nutrient that
functions in a number of physiological processes vital to
normal neonatal growth and development [1]. With
transition to extrauterine life the carbohydrate rich,
low-fat umbilical blood supply is replaced by the high
fat, low glucose diet of the breast milk. This switch in
nutrition source requires rapid physiological adaptations
in the newborn to enhance gluconeogenic processes
and fatty acid oxidation pathways to meet the energy* Correspondence: jane.alcorn@usask.ca
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reproduction in any medium, provided the ordemands of developing neonate. L-Carnitine plays an
important role in the enhancement of fatty acid
utilization during this adaptive period and throughout
postnatal development [1]. By regulating the movement
of long chain fatty acids into mitochondria and making
them available for β-oxidation, L-carnitine has an ob-
ligatory function in cellular energy production. Further-
more, L-carnitine has a role in the removal of toxic
fatty acyl-CoA metabolites from the mitochondria to
maintain an appropriate balance between free carnitine
and its acylated forms [2]. This vital role in cellular
metabolism identifies L-carnitine as essential to the
maintenance of normal mitochondrial function and in
the prevention of disease [2]. Any disruption in thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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uration might adversely impact the developing and
growing neonate [3].
L-Carnitine homeostasis represents a balance between
1) de novo biosynthesis, 2) intestinal absorption from
dietary sources, 3) uptake and release by the tissues,
and 4) renal reabsorption [4]. In early postnatal life,
L-carnitine biosynthesis is limited as a result of immature
γ-butyrobetaine hydroxylase activity (Bbh) (approxi-
mately 10-12 % adult levels), the enzyme that mediates
the last step in L-carnitine biosynthesis [5-7], but not
trimethyllysine hydroxylase (Tmlh) activity, the first
enzyme in L-carnitine biosynthesis [6]. The activity of
Bbh increases with age and reaches adult values later
in postnatal development [6,8]. Delayed Bbh maturation
suggests a reliance on dietary L-carnitine sources partic-
ularly during the immediate postnatal period.
Dietary L-carnitine is absorbed across the gastrointes-
tinal mucosa by active transport systems at the luminal
enterocytic membrane [4]. Membrane transporters, in
particular the organic cation/carnitine transporters
(Octn1, Octn2, and Octn3), also mediate the tissue dis-
tribution and renal reabsorption of L-carnitine and thus
play a critical role in L-carnitine homeostasis [9-11]. Of
these Octn transporters, Octn2 is the major high affinity
sodium-dependent L-carnitine transporter [12,13] that
plays a major role in regulating plasma and tissue pools
of L-carnitine. Octn transporters might undergo changes
in expression with postnatal maturation, but limited data
are available on their ontogeny in different tissues
[12,14,15].
As major components of the L-carnitine shuttle sys-
tem, L-carnitine acyltransferase enzyme (Cpt) systems
play important roles in fatty acid metabolism and energy
production and maintaining an appropriate balance be-
tween free and acylated fatty acids [16]. Cpt1 on the
mitochondrial outer membrane catalyses the first step of
mitochondrial import of long chain fatty acids by con-
verting them from fatty acyl-CoA to acylcarnitines [17].
On the inner mitochondrial membrane Cpt2 reconverts
the acylcarnitines to the respective CoA esters releasing
free L-carnitine and making fatty acids available for β-
oxidation [18]. Limited information is also available on
the ontogeny of Cpt enzymes.
Given our limited understanding of the ontogenesis of
L-carnitine homeostasis pathways, we conducted a sys-
tematic evaluation of the developmental changes in tis-
sue L-carnitine levels, tissue Octn mRNA expression
and immunohistochemistry, liver Bbh expression and ac-
tivity, heart Cpt1b and Cpt2 expression and activity, and
heart high energy phosphate compounds at different
postnatal ages with consideration of the known matur-
ation of L-carnitine biosynthesis for the rat [19]. At each
postnatal age, these evaluations were conducted intissues sampled from the same animal to avoid the
expected interindividual variability and replicated such
that the sample size was four animals per postnatal age
group. Such a systematic evaluation is important for
investigations into environmental and pathophysiological
factors that might impact the normal maturation of
these processes and the long-term impact on health and




Female Sprague–Dawley rats ordered at different gesta-
tion stages were obtained from Charles River Canada
(St. Constant, PQ) and were housed singly in a tem-
perature and humidity controlled facility (22 °C ± 2 °C)
on a 12-hour light:dark cycle (0700 h – 1900 h). All
rats were allowed a 7-day acclimatization period and had
free access to food (ProlabW RMH 3000, Purina, Inc.,
Richmond, IN) and water throughout the study. The
dams were closely monitored near parturition to identify
the exact time of birth. At birth, the litter size was
equalized to 10 pups per dam. The dam was considered
the experimental unit (n = 6) and blood and tissues were
pooled from 5 pups from each dam to carry out the vari-
ous analyses. Rat pups at postnatal day (PD) 4, 8, 11 and
20 were anaesthetized with isoflurane, and blood (200 –
500 μL depending on age) was collected by intracardiac
puncture. The rats were immediately sacrificed and
heart, intestine, kidney, and liver were rapidly excised
and flash-frozen in liquid nitrogen with storage at −80 °
C until analysis. All procedures were conducted in ac-
cordance with the Canadian Council of Animal Care
guidelines for the care and use of laboratory animals and
were approved by the Animal Research Ethics Board of
the University of Saskatchewan.
RNeasy Midi kits were obtained from Qiagen Inc.
(Mississauga, ON). The QuantiTect SYBR Green RT-
PCR kit was from Applied Biosystems (Foster City, CA).
The Advanced Protein Assay kit was obtained from
Fluka (Buchs, Switzerland). L-Carnitine and other che-
micals not otherwise specified were obtained from
Sigma-Aldrich (St. Louis, MO) and were the highest
purity grade available.
L-Carnitine Analysis in Serum and Heart
Serum and heart L-carnitine was quantified by HPLC-
UV with pre-column derivatization according to Feng
et al. [20]. Briefly, the pooled heart samples were homo-
genized with phosphate buffer (50 mM, pH 7.4) in a
ratio of 50 mg tissue:250 μL buffer. The homogenate
was centrifuged at 2500 × g for 10 min at 4 °C. The
supernatant or serum (20 μL) sample was precipitated
using acetonitrile and methanol (9:1 v/v). A 300 mg
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of KH2PO4 were added followed by a 1 h vortex mixing.
Derivatization reagent (40 mg/mL ρ-bromophenacyl
bromide with 50 μL 40 % tetrabutylammonium hydrox-
ide solution) was added into the organic extract. The re-
action mixture was incubated at 60 °C for 2 h followed
by centrifugation at 12,000 × g for 15 min. L-Carnitine
was analyzed using a Hewlett Packard 1050 HPLC sys-
tem with Diode Array Detector, Quaternary Pump and
Autosampler. Samples (10 μL) were injected onto a CN
(cyano) column (HyperClone 5 μm, 250 × 4.6 mm, Phe-
nomenex, Torrance, CA) with detection wavelength set
at 260 nm. The mobile phase (90 % acetonitrile/10 mM
citric-phosphate buffer, pH 3) was delivered at a flow
rate of 1 mL/min. The standard curve range was linear
(r2 >0.99) between 2.5-40 μmol/L. Intra- and interassay
accuracy and precision ranged from 6 %-14 %.
Heart Carnitine Palmitoyltransferase (Cpt) Enzyme
Activities
Heart Cpt enzyme activities were measured using the
spectrophotometric method described by Bieber et al.
[21]. Briefly, frozen heart tissue was homogenized in
10 % (wt/v) homogenization buffer (20 mM HEPES,
140 mM KCl, 10 mM EDTA and 5 mM MgCl2, pH 7.4)
supplemented with 3 mg nagarse using Polytron homo-
genizer (Brinkmann Instruments, Rexdale, Canada). The
homogenate was then centrifuged at 500×g for 10 min
at 4 °C. The supernatant was collected in new tubes
and centrifuged at 9000×g for 35 min at 4 °C. The pellet
was then washed with the homogenization buffer with-
out nagarse and centrifuged at 9000×g for 35 min at
4 °C. The washed pellet was resuspended in 200 μL
homogenization buffer without nagarse. Protein concen-
trations were measured using the Advanced Protein
Assay kit with bovine serum albumin as standard. The
optimal protein concentration and reaction time to give
linear product formation were initially determined. To
determine total Cpt activity 20 μg protein was assayed in
200 μL mL reaction buffer containing 20 mM HEPES,
1 mM EGTA, 220 mM sucrose, 40 mM KCl, 0.1 mM
5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB), 1.3 mg/mL
BSA, and 40 μM palmitoyl-CoA, pH 7.4. The reactions
were initiated by adding 1 mM L-carnitine and read at
412 nm after 5 min incubation at 37 °C using Synergy
HT Multi-Mode Microplate Reader (Biotek instrument,
USA). Cpt2 activity was determined using the same reac-
tion conditions as total Cpt except 10 μL (0.2 mM) Cpt1
inhibitor, malonyl-CoA, was added into 200 μL of the
reaction mixtures to obtain a final concentration of 10 μM.
Cpt1 activity was calculated by subtracting the Cpt2 ac-
tivity from the total Cpt activity. The Cpt activity was cal-
culated as amount of CoASH released per min per mg
protein, which is based on the 5-thio-2-nitrobenzoateformation from CoASH-DNTB reaction. The extinction
coefficient for 5-thio-2-nitrobenzoate was 13.6 mM/cm
and was used to calculate enzyme activity [22].
Liver γ-Butyrobetaine Hydroxylase (Bbh) Enzyme Activity
The liver tissue was homogenized in homogenization
buffer consisting of 300 mM sucrose, 1 mM EGTA, and
50 mM Tris, pH 7.5 using 1:4 mass to volume ratio. The
homogenate was then centrifuged at 13,000×g for
30 min at 4 °C. The supernatant was collected and cen-
trifuged at 100,000×g for 1 h at 4 °C. 300 μL of the
supernatant representing the cytosolic fraction contain-
ing Bbh was then transferred into a dialysis tubing cellu-
lose membrane (molecular weight cutoff of 12,000 Da,
D9777, Sigma, USA), and submerged in 5 L dialysis buf-
fer (75 mM KCl, 0.1 mM DTT and 0.5 mM EDTA in so-
dium phosphate buffer, pH 7.4) overnight at 4 °C. The
dialyzed sample (20 μL) was tested for L-carnitine resi-
due and the remaining dialysate was stored at −80 °C for
Bbh testing. The optimal protein concentration, sub-
strate concentration and reaction time to give linear
product formation was determined for each age group.
For determination of Bbh activity in rat pup liver, 1 mL
reaction buffer consisting of 0.2 mM γ-butyrobetaine,
20 mM potassium chloride, 3 mM 2-oxoglutarate,
10 mM sodium ascorbate, 0.4 mg/mL catalase in 20 mM
potassium phosphate buffer pH 7.0 was prepared. The
reaction was initiated by adding 2 μL ferrous ammonium
sulfate [23] (final concentration: 0.25 mM) and 20 μL
dialyzed enzyme into 78 μL reaction buffer and incu-
bated for 25 min at 37 °C using a Boekel/Grant Orbital
and Reciprocating Water Bath (Model ORS200, Expo-
tech, USA). The reaction was then terminated by adding
10 times the volume of acetonitrile:methanol (9:1).
The mixture was centrifuged at 13,000×g for 2 min
and the supernatant was used for L-carnitine analysis
by HPLC.
Total mRNA Isolation and Quantitative RT-PCR Analysis
Total mRNA was extracted from different tissues using
Qiagen RNeasy Midi Kits according to manufacturer
instructions. RNA purity and quantity were determined
spectrophotometrically by measurement at 260 nm and
the OD260/OD280 ratio, respectively, with a Synergy HT
Multi-Mode Microplate Reader (Biotek instrument,
USA). Total RNA was stored at −80 °C until analysis.
Gene sequences were obtained from the National Center
for Biotechnology Information GeneBank and specific
primers were designed using Primer3 software (White-
head Institute for Medical Research. Primer 3: http://
frodo.wi.mit.edu/primer3/) (Table 1). Quantitative RT-
PCR (QRT-PCR) analysis was carried out using a Quan-
tiTect SYBR Green RT-PCR kit and an Applied Bio-
systems 7300 Real-Time PCR system. The QRT-PCR
Table 1 Primer sequences for quantitative RT-PCR of rat






β-actin NM_031144 agcgtggctacagcttcacc tgccacaggattccataccc
Octn1 NM_022270 catggctgtgcagactgg gcaccatgtagccgatgg
Octn2 NM_019269 ggcgcaaccacagtatcc ggggctttccagtcatcc
Octn3 NM_019723 gacaccgtgaacctgagc ccatccaggcagttctcc
Cpt1b NM_013200 cagccatgccaccaagatc aagggccgcacagaatcc
Cpt2 NM_012930 gctccgaggcgtttctca tggccgttgccagatagc
Bbh NM_022629 acgatggggcagagtcc ctggcctcctgagaaaagc
Tmlh NM_133387 aatgtccctcccactcagg tcggtatggcgatctaggg
Octn, organic cation/carnitine transporter; Cpt, carnitine palmitoyltransferase;
Bbh, γ-butyrobetaine hydroxylase; Tmlh, trimethyllysine hydroxylase.
Ling et al. Nutrition & Metabolism 2012, 9:66 Page 4 of 10
http://www.nutritionandmetabolism.com/content/9/1/66protocol was carried out according to manufacturer’s
instructions. The protocol consisted of reverse transcrip-
tion (1 cycle at 48 °C, 30 minutes), PCR initial activation
step (1 cycle at 95 °C, 15 minutes), three-step thermal-
cycling (40 cycles; denaturing at 94 °C, 15 seconds,
annealing at 60 °C, 30 seconds, and primer extension at
60 °C for 30 seconds), and a melt curve analysis from
65 °C-95 °C at 0.5 °C/second.
Validation of Primers
Quantitative RT-PCR assays were initially optimized to
give PCR efficiency between 1.9-2.1 (as determined by a
3-point standard curving using serial dilutions of control
RNA with a slope range of −2.9 to −3.5) and a single
melt-peak corresponding to the appropriate PCR prod-
uct as verified by 2 % agarose gel electrophoresis. In
addition, the amplification efficiency of each target and
β-actin was determined by constructing a standard curve
from the crossing point (CT) value and RNA concentra-
tion. The target genes and β-actin were then amplified
using the same diluted samples. The ΔCT values were
calculated (i.e. the difference between the target gene CT
and β-actin CT). The slope from log RNA concentration
versus ΔCT was close to zero (<0.1). Only primers giv-
ing PCR amplification close to 100 % and relative effi-
ciencies between the target and β-actin that were
approximately equal were used in our experiment.
Heart High Energy Phosphate Substrate Determination
The heart high energy phosphate substrate levels includ-
ing creatine (Cr), creatine phosphate (CrP), ATP, ADP
and AMP were measured with HPLC-UV method as
described by Olkowski et al. [24]. The heart samples
were homogenized in 0.7 M ice-cold perchloric acid
(MW 100.46 D) with a final concentration 100 mg/mL.
The homogenate was centrifuged at 12,000 rpm for 5
minutes. The supernatant was collected and neutralized
with 2 M potassium hydroxide to bring pH near to 7.0.The supernatant was then filtered through a 0.45 μm
filter (Nonsterile Syringe Filter Nylon, Chromatographic
Specialties Inc. Brockville, Ontario, Canada) and 10 μL
was injected onto a 3 μm Luna C18 (Phenomenex, Tor-
rance, CA) column using gradient flow conditions. Two
mobile phase components used included 20 mM potas-
sium phosphate buffer (pH 7.0) and 100 % methanol.
The gradient was 100 % phosphate buffer from 0–
6.5 min, 100 % methanol from 6.5–12.5 min, and 100 %
phosphate buffer from 12.5 to 25 min for column re-
equilibration, which was sufficient to achieve stable
baseline conditions. The high-energy phosphate sub-
strates including CrP, Cr, ATP, ADP and AMP were
monitored at 210 nm. The standard curve range was
from 6.25-100 μg/mL and the limit of detection was
0.078 μg/mL for ATP and 0.312 μg/mL for ADP and
AMP. Intra- and interassay accuracy and precision ran-
ged from 4.2 % to 14.5 %.
Immunohistochemistry
Intestine and kidney from neonatal rat pups were rapidly
harvested and fixed by immersion in 4 % paraformalde-
hyde. Paraffin imbedded sections (5 μm) were prepared
by standard procedures and sections were incubated
with Octn antibodies (1:100) (Alpha Diagnostic Inter-
national) for 1 h followed by (H+L)-peroxidase-conju-
gated affinity-pure goat anti-rabbit IgG (1:500) for
30 min. Immunoreactions were visualized by using VIP
Substrate kit for peroxidase (Vector Laboratories)
according to manufacturer instructions. Non-specific
binding was tested by using premixed control peptide
with the respective Octn antibodies. For negative con-
trols, only secondary antibody was applied to the slides.
Statistical Analysis
All data are reported as mean± SEM. One-way ANOVA
with Tukey’s post hoc test was used for the comparisons
between ages. A P< 0.05 was chosen as the level of stat-
istical significance. Pearson's correlation coefficients
were computed to quantify the association between
heart L-carnitine concentration and heart Octn2 mRNA
expression levels as well as serum L-carnitine concentra-
tion and kidney Octn2 mRNA expression.
Results
To examine the ontogenesis of critical components of
the L-carnitine homeostasis pathway we conducted an
mRNA expression and activity analysis of various com-
ponents of the homeostasis pathway in different tissues
of rat pups of different postnatal ages. Serum free
L-carnitine concentrations (Figure 1A) increased sig-
nificantly between postnatal day (PD) 4 and PD11 (PD11
L-carnitine concentrations were approximately 20 % higher
than PD4) and stayed reasonably stable after PD11.














































Figure 1 Mean± SEM free L-carnitine concentration in rat (A) serum and (B) heart tissue (n= 6) at postnatal day 4, 8, 11, and 20.
L-Carnitine concentration was determined using HPLC-UV as described in text. One-way ANOVA with Tukey’s post hoc test was used for the
comparisons between ages and bars with the same letters indicate no significant difference, P< 0.05.
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relatively similar at PD4, PD8 and PD11, but a signifi-
cant increase was observed between PD11 and PD20
(heart L-carnitine concentrations were approximately
50 % greater at PD20 relative to PD4).
mRNA expression of key L-carnitine transporters,
the Octns, were evaluated in the heart, kidney, and in-
testine by QRT-PCR. Generally, heart Octn1 mRNA
expression (Figure 2A) remained constant, except at
PD8, where expression was statistically higher than all
other PD age groups. Heart Octn2 expression
(Figure 2A) increased postnatally (approximately 100 %
increase in expression at PD11 relative to PD4), al-
though increases in expression after PD11 were not
statistically significant. Although not statistically signifi-
cant, heart Octn3 mRNA expression (Figure 2A) was
lowest at PD4 while expression was approximately
200 % higher at PD8 and remained relatively constant
thereafter. A strong (r = 0.823) and significant correl-
ation (P< 0.05) (Figure 3B) was observed between
heart free L-carnitine concentrations and heart Octn2
mRNA expression in rat pups at different postnatal
age groups.
In the kidney, Octn1 and Octn3 mRNA expression
(Figure 2B) was relative stable throughout postnatal de-
velopment, although PD11 demonstrated a statistically
significant decrease in expression relative to all other PD
age groups. This consistent result between Octn1 and
Octn3 likely has limited importance as it probably
results from expected interindividual variation and the
use of a destructive sampling strategy. Kidney Octn2 ex-
pression (Figure 2B) increased in the postnatal period,
although increases in expression after PD11 were not
statistically significant. Serum free L-carnitine concen-
trations were significantly correlated (r = 0.462) to kidney
Octn2 mRNA expression (P< 0.05) (Figure 3A) in rat
pups at different postnatal age groups.
In the intestine, Octn1 mRNA expression (Figure 2C)
was low at PD4 but demonstrated a statisticallysignificant increase (approximately 200 %) at PD8. Ex-
pression at PD20 was similar to PD8, although PD11
demonstrated a statistically significant decrease in expres-
sion relative to PD8 and PD20. Relative to Octn1 mRNA
expression, intestinal Octn2 and Octn3 mRNA expression
(Figure 2C) was high in the early postnatal period. Expres-
sion of Octn2 and Octn3 remained relatively constant
through the remaining postnatal period.
The postnatal increase in liver Bbh mRNA expression
generally mirrored the increase in Bbh activity (Figure 4).
Although not statistically significant, Bbh mRNA expres-
sion (Figure 4A) increased approximately 50 % between
PD4 and PD8 with a statistically significant increase
(more than 100 %) between PD8 and PD20. An approxi-
mately 400 % increase in liver Bbh activity (Figure 4B)
was observed between PD4 and PD11 and activity
remained relatively constant thereafter.
Heart Cpt1b and Cpt2 and liver Tmlh mRNA expres-
sion (Figure 5A and 5B) remained constant in the early
postnatal period with significant increases in expression
(approximately 50 %) occurring only between PD11 and
PD20 for Cpt enzymes, while no change in Tmlh mRNA
expression was observed with postnatal age. Despite this
increase in Cpt mRNA expression in the late postnatal
period, no significant differences in Cpt enzyme activity
(Figure 6) were found at all examined postnatal ages.
In addition, heart high energy phosphate concentrations
(Figure 7) remained relatively constant through post-
natal development. The heart concentrations of creatine
(Figure 7) increased significantly during postnatal devel-
opment. An almost 250 % increase in heart creatine
concentrations was observed between PD4 and PD8
and a more than100% increase between PD8 and PD20.
Creatine phosphate levels in postnatal cardiac tissue
(Figure 7) remained relatively constant at all postnatal
age groups.
Immunohistochemical staining with Octn antibodies
was performed to determine Octn expression in kidney,

































































































































Figure 2 Mean± SEM organic cation/carnitine transporter
(Octn) mRNA expression (Octn1 – white bar; Octn2 – light grey
bar; Octn3 – dark grey bar) in rat (A) heart, (B) kidney, and (C)
intestine at postnatal day 4, 8, 11, and 20 (n= 6). mRNA
expression was normalized to β-actin and fold difference (FD) was
determined by using 2-ΔΔCT method. One-way ANOVA with Tukey’s
post hoc test was used for the comparisons between ages and bars
with the same letters indicate no significant difference, P< 0.05.
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control and no further evaluations were conducted.Discussion
During postnatal development, a number of nutrient
homeostasis pathways undergo ontogenesis to satisfy the
nutrient requirements for growth and development.Although many of the developmental changes in these
nutrient homeostasis pathways are genetically pro-
grammed, exogenous factors such as dietary compo-
nents, environmental compounds and therapeutic drugs
might affect their maturation. Our laboratory is inter-
ested in the developmental outcomes of interactions be-
tween drugs and nutrients that share the same
absorption and/or disposition (i.e. distribution, elimin-
ation mechanisms) mechanisms. Our investigations
began with L-carnitine homeostasis pathways and we
systemically evaluated the ontogeny of key L-carnitine
homeostasis pathways in the rat. Such information can
help us to further understand the impact of exogenous
factors on the maturation of nutrient homeostasis pro-
cesses and the possible long-term consequences of drug-
nutrient interactions during ontogeny.
In mammals, fatty acid oxidation becomes the main
source of energy for many tissues with transition to
extrauterine life [25]. Mitochondrial fatty acid utilization,
though, requires a sufficient supply of L-carnitine to
shuttle long-chain fatty acids across the mitochondrial
membrane making them available for β-oxidation [2].
The maternal circulation supplies L-carnitine to the
developing fetus. During late gestation, L-carnitine con-
centrations significantly increase in fetal tissues and this
storage of L-carnitine assures adequate levels in the im-
mediate postpartum period [9,26]. These tissue stores
quickly become depleted due to the immaturity of many
of the L-carnitine homeostasis mechanisms and main-
tenance of L-carnitine concentrations requires an ex-
ogenous source (i.e. milk) of L-carnitine [9]. In our
study, postnatal increases in serum free L-carnitine were
consistent with levels reported in the literature [27] and
these increases correlated with maturation of a number
of enzymes and transporter systems that critically deter-
mine L-carnitine levels in the body.
Lower serum free L-carnitine levels in the early post-
natal period is, in part, due to the limited capacity for
endogenous biosynthesis by the young neonate [5,19].
As noted in other studies, TLMH mRNA expression
remained constant with postnatal development [6] and
in agreement with other studies we found that hepatic
γ-Bbh mRNA expression and activity was significantly
lower at early postnatal development in rat pups [19,28].
Young neonates are highly dependent on exogenous
sources of L-carnitine, which is usually supplied in suffi-
cient amounts by the breast milk during nursing [29].
Interestingly, L-carnitine levels in the milk of nursing rat
dams decrease significantly by mid-lactation [30,31].
Despite the reduced exogenous L-carnitine, serum free
L-carnitine levels in rat pups increase with advancing
age [27]. The maturation of hepatic γ-Bbh contributes to
the postnatal increase in L-carnitine levels in the body.























































































Figure 3 (A) Correlation between rat kidney Octn2 mRNA expression and serum free L-carnitine concentration (Pearson’s r = 0.462).
(B) Correlation between heart Octn2 mRNA expression and heart free L-carnitine concentration (Pearson’s r = 0.823).
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renal reabsorption of L-carnitine additionally contribu-
ted to the postnatal rise in serum L-carnitine.
Absorption of dietary sources of L-carnitine requires
the function of several transporter systems expressed at
the gastrointestinal epithelial barrier [25]. In our study
expression of small intestinal Octn2 and Octn3 did not
change with postnatal development, while Octn1 expres-
sion increased significantly between PD4 to PD8
remaining relatively constant after PD8. A previous
study, which examined the postnatal maturation of the
intestinal uptake L-carnitine, noted that Na+-dependent
and Na+-independent intestinal uptake of L-carnitine
was high in late gestation and in the newborn and sig-
nificantly decreased between PD1 and PD15 [32]. Fur-
thermore, mRNA expression of Octn2 demonstrated
only a 20 % decrease between PD1 and PD15 in the
jejunum, while ileal expression demonstrated a 100 %
decrease between these two postnatal age groups [32].
In our study Octn2 mRNA expression was evaluated
in the jejunum, and the constant expression of Octn2
and Octn3 is consistent with these findings. Octn2
and Octn3 mediates the Na+-dependent uptake of













































Figure 4 Mean± SEM rat liver gamma-butyrobetaine hydroxylase (Bb
and 20 (n = 6). mRNA expression was normalized to β-actin and fold differ
measured by quantifying the conversion of γ-butyrobetaine to L-carnitine b
the comparisons between ages and bars with the same letters indicate nonot statistically significant, our data demonstrates that
Octn2 expression did decrease at PD11 and PD20 and
Octn3 at PD20, which might suggest a reduced ability to
absorb L-carnitine with advancing postnatal age as pre-
viously reported [32].
Renal reabsorption of L-carnitine from the urinary
filtrate plays a significant role in maintenance of
L-carnitine levels in the body. Almost 95 % of the excreted
L-carnitine is reabsorbed by transporters expressed in
the proximal tubules of the kidney with Octn2 as the
principal transporter involved in this process [12]. In our
study renal Octn2 expression increased during post-
natal development in the rat, which is consistent with
the literature [12,14,34]. The increase in renal Octn2
expression correlated strongly with increases in serum
L-carnitine levels suggesting that renal Octn2 plays
a significant role in the postnatal pattern of serum
L-carnitine development. Overall our data suggest the
developmental changes in hepatic γ-Bbh expression, in-
testinal Octn1 expression, and renal Octn2 expression
might systemically contribute to the postnatal increase
in serum L-carnitine levels. However, the precise inter-
connections of these pathways and their overall contri-




































h) (A) mRNA expression and (B) activity at postnatal day 4, 8, 11,
ence (FD) was determined by using 2-ΔΔCT method. Bbh activity was
y HPLC-UV. One-way ANOVA with Tukey’s post hoc test was used for
significant difference, P< 0.05.













































































Figure 5 Mean± SEM mRNA expression of (A) heart carnitine palmitoyltransferase 1b (Cpt1b) (light grey bar) and carnitine
palmitoyltransferase 2 (Cpt2) (black bar), and (B) hepatic trimethyllysine hydroxylase (Tmlh) in rat pups at postnatal day 4, 8, 11, and
20 (n= 6). mRNA expression was normalized to β-actin and fold difference (FD) was determined by using 2-ΔΔCT method. One-way ANOVA with
Tukey’s post hoc test was used for the comparisons between ages and bars with the same letters (mRNA expression levels) or same symbol
(activity levels) indicate no significant difference, P< 0.05.
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http://www.nutritionandmetabolism.com/content/9/1/66not known and further studies are required to clarify
their contributions.
The distribution of L-carnitine in the body is organ
dependent with the highest concentration of L-carnitine
in the heart [35]. In our study, heart L-carnitine levels
increased during postnatal development and these
increases were correlated with increased expression of
Octn2 in the heart. L-Carnitine has a significant function
in energy production in neonatal cardiac tissue due to
its role in fatty oxidation and the reliance of neonatal
hearts on fatty acids as the primary energy substrate
[36]. The dramatic increase in fatty acid oxidation rates
in early heart development after birth has been attribu-
ted to an increase in L-carnitine levels [36]. Although we



































Figure 6 Mean± SEM heart carnitine palmitoyltransferase 1b
(Cpt1b) (light grey bar) carnitine palmitoyltransferase 2 (Cpt2)
(dark grey bar) activity in rat pups at postnatal day 4, 8, 11,
and 20 (n = 6). Heart Cpt enzyme activities were measured using
the spectrophotometric method described by Bieber et al. [21].
One-way ANOVA with Tukey’s post hoc test was used for the
comparisons between ages and bars with the same symbol (Cpt1)
or same letters (Cpt2) indicate no significant difference, P< 0.05.the heart with advancing age of the neonate, cardiac
ATP levels remained constant through postnatal devel-
opment. Interestingly, we found that creatine and ADP
levels were ontogenically regulated during postnatal de-
velopment. The significance of such developmental
changes is not clear and requires investigation.
We also evaluated heart Cpt enzyme expression and
activity due to the pivotal role of these enzymes in heart
energy production. The postnatal increase in both Cpt1b
and Cpt2 mRNA expression at postnatal day 20 are par-
alleled by the increases in heart L-carnitine concentra-
tions. Indeed, Cpt1a and Cpt2 mRNA levels were
increased by carnitine administration in cell culture
systems [37]. Thus, the significant increase in heart





















































Figure 7 Mean± SEM heart high-energy phosphate substrate
concentration in rat pups at postnatal day 4, 8, 11, and 20
(n= 6). The heart high energy phosphate substrate levels including
creatine (Cr), creatine phosphate (CrP), ATP, ADP and AMP were
measured with HPLC-UV method as described by Olkowski et al.
[24]. One-way ANOVA with Tukey’s post hoc test was used for the
comparisons between ages and bars with the same symbol indicate
no significant difference, P< 0.05. (Cr – creatine; CrP – creatine
phosphate).
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http://www.nutritionandmetabolism.com/content/9/1/66the transcriptional enhancement of both Cpt1b and
Cpt2. Despite these transcriptional increases in Cpt
enzymes, we observed no significant changes in heart
Cpt enzyme activity. Cpt enzyme activities have been
reported to increase with increasing mitochondrial
L-carnitine levels [38-40]. Unfortunately, L-carnitine
levels in the whole heart tissue rather than in the mito-
chondria were measured in our study.
In conclusion, several L-carnitine homeostasis path-
ways underwent significant ontogenesis during postnatal
development in the rat. However, the exact relation-
ship between these pathways and their contribution to
L-carnitine homeostasis during development is not com-
pletely known and further studies are required to clarify
their contributions. Such a clarification is necessary to
understand the impact of exogenous and endogenous
factors on L-carnitine status during development. None-
theless, this systematic evaluation of key pathways in the
L-carnitine homeostasis pathway provides a basis from
which we can conduct further evaluations regarding the
effects of exogenous (i.e. drug) and endogenous factors
(i.e. disease) on L-carnitine status during postnatal de-
velopment and possible long-term consequences of any
disturbance in the normal ontogeny of these pathways.
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